Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T15000
|
||||
Former ID |
TTDC00259
|
||||
Target Name |
Cytotoxic T-lymphocyte protein 4
|
||||
Gene Name |
CTLA4
|
||||
Synonyms |
CD152; CTLA-4; Cytotoxic T-lymphocyte-associated antigen 4; CTLA4
|
||||
Target Type |
Successful
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Late-stage melanoma; Prostate cancer [ICD9:172, 185; ICD10: C43, C61] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
Possibly involved in T-cell activation. Binds to B7-1 (CD80) and B7-2 (CD86).
|
||||
BioChemical Class |
Immunoglobulin
|
||||
Target Validation |
T15000
|
||||
UniProt ID | |||||
Sequence |
MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEY
ASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLR AMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFL LTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cell adhesion molecules (CAMs) | ||||
T cell receptor signaling pathway | |||||
Autoimmune thyroid disease | |||||
Rheumatoid arthritis | |||||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
Reactome | CTLA4 inhibitory signaling | ||||
WikiPathways | Vitamin D Receptor Pathway | ||||
T-Cell Receptor and Co-stimulatory Signaling | |||||
Allograft Rejection | |||||
Costimulation by the CD28 family | |||||
References | |||||
Ref 525318 | ClinicalTrials.gov (NCT02551159) Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.